基于专利分析的Bcr-Abl抑制剂类药物的研发进展  

Research progress of Bcr-Abl inhibitors based on patent analysis

作　　者：李静 张静 王银香 LI Jing;ZHANG Jing;WANG Yin-xiang(Library and Information Centre of China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学图书与信息中心,南京211198

出　　处：《中国新药杂志》2023年第1期8-15,共8页Chinese Journal of New Drugs

基　　金：2021年度江苏省图书馆大数据研究立项课题资助项目(2021JSTD011)。

摘　　要：Bcr-Abl抑制剂是治疗慢性髓细胞白血病(CML)的靶点类药物,因靶点类药物选择性高、不良反应少,其中有些已成为治疗CML的一线用药,Bcr-Abl抑制剂也因此成为抗CML药物的研究热点。本文以Bcr-Abl抑制剂的专利公开信息为基础,从公开时间、区域分布等分析Bcr-Abl抑制剂的研究发展态势,并通过技术主题对比分析国内外的研发进展,最后选取国内外各1家企业对其药物研发后续专利申请进行分析,以期为该类药物的研发提供相关参考。Bcr-Abl inhibitors are targeted drugs for the treatment of chronic myeloid leukemia(CML).Due to the high selectivity with few side effects,some of them have become the first-line drugs in the treatment of CML.Therefore,Bcr-Abl inhibitors have become the hotspot of anti-CML drug research.Based on the patent publication records of Bcr-Abl inhibitors,this article analyzes the research and development trends of Bcr-Abl inhibitors from the publication time and regional distribution,compares and analyzes the research progress through technical topics,and finally selects an enterprise to analyze its subsequent patent application for drug research and development in China and abroad,in order to provide relevant reference for the research and development of Bcr-Abl inhibitors.

关 键 词：BCR-ABL 酪氨酸激酶 慢性髓细胞白血病 专利分析 药物早期研发情报数据库 

分 类 号：R95[医药卫生—药学]